EEF2 and cholangiocarcinoma: RFC4, HDGF, and TPM4 showed higher gain mutation frequencies, while eukaryotic translation elongation factor 2 (EEF2) and ENO1 had higher loss mutation frequencies across ovarian serous cystadenocarcinoma, uterine carcinosarcoma, and cholangiocarcinoma.